08h00 – 09h00 | HALL A3 | Oncopolicy Forum: Inequalities in Treatment Outcomes
Co-Chair: M. Piccart
Co-Chair: I. Banks
Inequalities between and within countries
R. Sullivan
The value of anticancer treatment
E.G. de Vries
Health Economics in Radiation Oncology (HERO) project
Y. Lievens
Industry perspective
M. Lees
Panel discussion
09h15 – 11h15 | HALL C3 | Scientific Symposium: ESMO Clinical Practice Guidelines
Chair: A. Cervantes
Co-Chair: G. Pentheroudakis
Introduction to the ESMO Clinical Practice Guidelines
A. Cervantes
Questionnaire
G. Pentheroudakis
Colon cancer case presentation
L. Salvatore
Discussant: D. Arnold
Questions & Answers
Multiple myeloma case presentation
C. Langer
Discussant: H.C. Schouten
Questions & Answers
Cancers of unknown primary site (CUP)
Y. Metaxas
Discussant: G. Pentheroudakis
Questions & Answers
Breast cancer case presentation: HER2+ metastatic disease after adjuvant trastuzumab
E. Saloustros
Discussant: E. Senkus-Konefka
Questions & Answers
11h30 – 12h30 | HALL D1 | Multidisciplinary Tumour Board: Breast Cancer
Chair: P. Poortmans
Case presentation by young oncologist: Early disease
I. Kindts
Panel Discussion: Early disease
Case presentation by young oncologist: Locally advanced disease
E. Vicini
Panel Discussion: Locally advanced disease
Case presentation by young oncologist: Advanced disease
M.V. Dieci
Panel Discussion: Advanced disease
Pathologist
H.G. Russnes
Medical Oncologist
F. Cardoso (Portugal)
Surgical Oncologist
I.T. Rubio
Pathologist
J. Reis-Filho
Oncology Nurse
Y. Wengström
13h00 – 14h30 | STOLZ 2 | Special Session: ESMO Women for Oncology
ESMO Women for Oncology Award 2015
Awardee: E. Felip
14h45 – 16h55 | HALL D1 | Presidential Session: Presidential Session II
Chair: E.G. de Vries
Chair: R. Marais
Pezcoller Foundation- ECCO Recognition for Contribution for Oncology Award
Awardee: K. Meier
ESMO Hamilton-Fairly Award
Awardee: C.J. Punt
1BA - BEST ABSTRACT: The impact of pathological factors on long-term local control in the EORTC boost no-boost trial
C. Vrieling
Discussant: J. Yarnold
5LBA - LATE BREAKING ABSTRACT: Everolimus in advanced nonfunctional neuroendocrine tumors (NET) of lung or gastrointestinal (GI) origin: Efficacy and safety results from the placebo-controlled, double-blind, multicenter, Phase 3 RADIANT-4 study
J. Yao
6LBA - LATE BREAKING ABSTRACT: 177-Lu-Dotatate significantly improves progression-free survival in patients with midgut neuroendocrine tumours: Results of the phase III NETTER-1 trial
P. Ruszniewski
Discussant: E. Grande
2BA - BEST ABSTRACT: The interval between primary melanoma excision and sentinel node biopsy (SNB) does not affect survival; regardless of SNB status - an EORTC Melanoma Group study
C. Oude Ophuis
Discussant: P. Naredi
15h15 – 16h15 | LEHAR 1 | Special Session: Nutrition and Body Image Changes - A Concern for All Patients with Cancer
Chair: M.C. Lacerda (Portugal)
Weight gain during cancer therapy: Issues for cancer practice
Y. Wengström
Swallowing difficulties: Lessons from head and neck cancer
M. Wells
Cancer cachexia: What can we do to help?
F. Strasser
17h00 – 18h30 | HALL C3 |Scientific Symposium: Therapeutic Implication of Intra Tumour Heterogeneity in Breast Cancer
Chair: A.L. Børresen-Dale
Co-Chair: C. Caldas
Inference of tumour evolution during chemotherapy
S. Aparicio
Heterogeneity, treatment response, and outcome in HER2-positive breast cancer
L. Carey
Role of liquid vs solid biopsies in monitoring treatment
C. Caldas (Portugal)
New frontiers in molecular imaging to improve targeting of high risk disease
E.G. de Vries
Discussion & Roundup
17h00 – 18h30 | THE STUDY | Special Session: ECCO-AACR-EORTC-ESMO Workshop on Methods in Clinical Cancer Research: How to Design Good Clinical Trials
Chair: J.R. van der Vorst
Introduction to the Workshop: Providing the right tools for young oncology professionals
S. Sleijfer
From Fellow to Faculty: How the Workshop inspired me
T. Yap
Assessing the impact of the Workshop on the careers of participants
S. Essiaf
Journey from young oncologist to establishing your career: Significance of improving clinical trial designs
F. Cardoso (Portugal)
Development of future trialists: An industry perspective
P. Haluska
Discussion
18h30 – 19h15 | SPOTLIGHT B2 | Meet the Satellite Symposium Expert : MSD - Meet The Expert at ECC 2015 "Case Studies in Advanced Melanoma"
Welcome and Introduction
J.J. Grob
Case 1: How Should Checkpoint Inhibitors Be Most Effectively Sequenced or Combined?
S. Agarwala
Case 2: Recognising and Managing Adverse Events With Anti-PD1 mAbs
J.J. Grob
Panel Discussion
Panel: All Faculty
Q&A and Close
J.J. Grob
19h00 – 20h30 | HALL A4 | Satellite Symposium: MSD - Immunotherapy for Cancer: Promise of the PD-1 Class of Checkpoint Inhibitors
Introduction
Chair: T. Seiwert
Rationale for Immunotherapy in Cancer: Proof of Concept
T. Seiwert
Audience Response Session (ARS): Quiz
Panel: T. Seiwert
Immunotherapy in Head and Neck Cancer: Results and Ongoing Clinical Trials
T. Seiwert
Immunotherapy in Gastric Cancer: Results and Ongoing Clinical Trials
M. Möhler
Audience Response Session (ARS) Quiz
Panel: M. Möhler
Immunotherapy in Bladder Cancer: Results and Ongoing Clinical Trials
J. Bellmunt
Immunotherapy in Triple-Negative Breast Cancer: Results and Ongoing Clinical Trials
L. Pusztai
Audience Response Session (ARS): Quiz
Panel: All Faculty
Closing
